Quintiles Expects Increase In Phase IV Business Following Vioxx Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
The company could see an “uptick” in late-phase study contracts based on internal initiatives and market dynamics from the Vioxx withdrawal, CFO Ratliff tells analysts.